Similar articles

• Systemic bioavailability of acebutolol in man.

  Roux A, Flouvat B, Fouache Y, Bourdarias JP. Roux A, et al. Biopharm Drug Dispos. 1983 Jul-Sep;4(3):293-7. doi: 10.1002/bdd.2510040309. Biopharm Drug Dispos. 1983. PMID: 6626703 No abstract available.
• Dose-dependent acebutolol disposition after oral administration.

  Meffin PJ, Winkle RA, Peters FA, Harrison DC. Meffin PJ, et al. Clin Pharmacol Ther. 1978 Nov;24(5):542-7. doi: 10.1002/cpt1978245542. Clin Pharmacol Ther. 1978. PMID: 699478
• Observations on the pharmacokinetics of acebutolol.

  Kaye CM, Kumana CR, Leighton M, Hamer J, Turner P. Kaye CM, et al. Clin Pharmacol Ther. 1976 Apr;19(4):416-20. doi: 10.1002/cpt1976194416. Clin Pharmacol Ther. 1976. PMID: 1269192 Clinical Trial.
• The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.

  Kirch W, Köhler H, Berggren G, Braun W. Kirch W, et al. Clin Nephrol. 1982 Aug;18(2):88-94. Clin Nephrol. 1982. PMID: 7140021
• The pharmacokinetics of acebutolol in man, following the oral administration of acebutolol HCl as a single dose (400 mg), and during and after repeated oral dosing (400 mg, b.d.).

  Gulaid AA, James IM, Kaye CM, Lewellen OR, Roberts E, Sankey M, Smith J, Templeton R, Thomas RJ. Gulaid AA, et al. Biopharm Drug Dispos. 1981 Apr-Jun;2(2):103-14. doi: 10.1002/bdd.2510020202. Biopharm Drug Dispos. 1981. PMID: 7248475